# Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)

> **NCT07468448** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Population Health Research Institute** · enrollment: 1172 (estimated)

## Conditions studied

- Ischemic Stroke
- Intracranial Atherosclerosis

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** ASA

## Key facts

- **NCT ID:** NCT07468448
- **Lead sponsor:** Population Health Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2029-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 1172 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07468448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07468448, "Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07468448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*